RXD:NYE-ProShares UltraShort Health Care (USD)

ETF | Trading--Inverse Equity |

Last Closing

USD 9.5537

Change

-0.08 (-0.78)%

Market Cap

N/A

Volume

1.81K

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-26 )

Largest Industry Peers for Trading--Inverse Equity

Symbol Name Price(Change) Market Cap
SH ProShares Short S&P500

-0.04 (-0.37%)

USD 1.12B
SOXS Direxion Daily Semiconductor B..

-2.23 (-10.60%)

USD 0.85B
PSQ ProShares Short QQQ

-0.27 (-0.68%)

USD 0.62B
SPXU ProShares UltraPro Short S&P50..

-0.29 (-1.18%)

USD 0.53B
SDOW ProShares UltraPro Short Dow30

-0.24 (-1.79%)

USD 0.29B
SPDN Direxion Daily S&P 500® Bear ..

-0.05 (-0.44%)

USD 0.16B
RWM ProShares Short Russell2000

-0.10 (-0.52%)

USD 0.16B
DOG ProShares Short Dow30

-0.15 (-0.56%)

USD 0.16B
DUST Direxion Daily Gold Miners Ind..

-0.08 (-1.61%)

USD 0.14B
LABD Direxion Daily S&P Biotech Bea..

-0.07 (-1.17%)

USD 0.11B

ETFs Containing RXD

RLD:CA 0.00 % 0.61 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Trading--Inverse Equity) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -19.92% 67% D+ 9% A-
Dividend Return 3.50% 60% D- 65% D
Total Return -16.42% 67% D+ 10% F
Trailing 12 Months  
Capital Gain -27.15% 71% C- 7% C-
Dividend Return 4.11% 68% D+ 57% F
Total Return -23.04% 69% C- 8% B-
Trailing 5 Years  
Capital Gain -79.18% 57% F 4% F
Dividend Return 2.14% 51% F 7% C-
Total Return -77.04% 57% F 4% F
Average Annual (5 Year Horizon)  
Capital Gain 1.87% 41% F 45% F
Dividend Return 2.90% 41% F 39% F
Total Return 1.03% 55% F 23% F
Risk Return Profile  
Volatility (Standard Deviation) 249.67% 61% D- 3% F
Risk Adjusted Return 1.16% 39% F 25% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.